All In Biotech

Drug Trial Radar · NCT04917315

To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Bridge Study to Evaluate the Efficacy and Safety of JLP-2002 in Patients With Overactive Bladder

Last checked: Nov 20, 2026Latest source record: Jan 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

May 21, 2020

Primary completion

Aug 18, 2021

Study completion Aug 18, 2021

Sponsor

Lead sponsor
Jeil Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Overactive bladder (OAB) is a clinical condition characterized by urgency (i.e., urinary urinary urinary urgency that is difficult to delay and unbearable) with or without urge incontinence, usually associated with frequency and nocturia. The main drug class used is antimuscarinics, and the clinical utility of antimuscarinic drugs is limited due to its mild efficacy and poor tolerability due to side effects of mechanisms such as dry mouth and constipation. In addition to poor tolerability and mild efficacy, recent literature suggests that long-term use of anticholinergics is associated with cognitive impairment and dementia. Therefore, the purpose of this study was to evaluate the treatment effect of overactive bladder symptoms through the change in the average number of urination per day after administration of JLP-2002, a beta 3-adrenergic receptor (β3-AR) agonist with an effective alternative mechanism, for 12 weeks.

Conditions

  • Overactive Bladder

Interventions

  • JLP-2002 A mgDrug

    administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.

  • PlaceboDrug

    administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Daily Micturitions at Week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.